Hashimoto's thyroiditis (autoimmune thyroiditis) is the most common cause of hypothyroidism in the United States. It is characterized clinically by a gradual decline in thyroid function due to the immune-mediated destruction of the gland tissue. Hashimoto’s thyroiditis is an inflammatory process, and since low dose naltrexone (LDN) appears to act as an immunomodulator it is can be an excellent adjunct therapy in clinical practice. Additionally, LDN use in patients with Hashimoto’s not only helps reduce a myriad of thyroid-associated symptoms, but can also lead to a reduced thyroid replacement dosing. Many people with Hashimoto’s often exhibit numerous sensitivities and aggravations to different therapies.
Learn the art of LDN prescribing in people with Hashimoto’s to maximize its therapeutic effects with minimal aggravations.